Clinical Academic in Cancer Immuno-oncology at Cardiff University.

Dr Savage trained in Medical Oncology at the Royal Marsden and Imperial Hospitals in London and has a PhD in the immunotherapy of cancer. Whilst working as a full time NHS Consultant he has been able to maintain an ongoing interest in translational cancer research.

Philip has worked on antibody-directed immunotherapy, in particular the sfv-IL-2 fusion protein and antibody targeted HLA class I complexes. These therapeutic approaches are both in clinical development, with the sfv-IL-2 fusion protein currently awaiting an FDA licencing decision.

He also has an interest in cancer epigenetics and chemotherapy sensitivity and led the group to first describe the route to oncogenesis of choriocarcinoma. Alongside these laboratory-based projects, Philip has also published a number of clinical papers predominantly in gynaecology oncology, urology oncology and health economics and overall has more than 150 clinical and scientific publications.